Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Drug Type
3.3. Snippet by Route of Administration
3.4. Snippet by Distribution Channel
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Investments in Research and Development
4.1.1.2. Advancements in Treatment Options
4.1.1.3. XX
4.1.2. Restraints
4.1.2.1. High Cost of Treatment
4.1.2.2. Limited Awareness and Diagnosis
4.1.2.3. XX
4.1.3. Opportunity
4.1.3.1. Emerging Non-Steroidal Therapies
4.1.3.2. XX
4.1.4. Impact Analysis
5. Strategic Insights and Industry Outlook
5.1. Market Leaders and Pioneers
5.2. Emerging Pioneers and Prominent Players
5.3. Established leaders with largest selling Brand
5.4. Market leaders with established Product
5.5. CXO Perspectives
5.6. Latest Developments and Breakthroughs
5.7. Case Studies/Ongoing Research
5.8. Regulatory and Reimbursement Landscape
5.9. North America
5.10. Europe
5.11. Asia Pacific
5.12. Latin America
5.13. Middle East & Africa
5.14. Porter’s Five Force Analysis
5.15. Supply Chain Analysis
5.16. Patent Analysis
5.17. SWOT Analysis
5.18. Unmet Needs and Gaps
5.19. Recommended Strategies for Market Entry and Expansion
5.20. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
5.21. Pricing Analysis and Price Dynamics
5.22. Key Opinion Leaders
6. By Type
6.1. Introduction
6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Type
6.1.2. Market Attractiveness Index, By Type
6.2. Classic Congenital Adrenal Hyperplasia*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Nonclassic Congenital Adrenal Hyperplasia
7. By Drug Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
7.1.2. Market Attractiveness Index, By Drug Type
7.2. Corticosteroids*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.2.3. Hydrocortisone
7.2.4. Prednisone
7.2.5. Dexamethasone
7.2.6. Fludrocortisone
7.3. Crinecerfont
7.4. Spironolactone
7.5. Others
8. By Route of Administration
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
8.1.2. Market Attractiveness Index, By Route of Administration
8.2. Oral*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Injectable
9. By Distribution Channel
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.1.2. Market Attractiveness Index, By Distribution Channel
9.2. Hospital Pharmacies*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Retail Pharmacies
9.4. Online Pharmacies
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.7.1. U.S.
10.2.7.2. Canada
10.2.7.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.7.1. Germany
10.3.7.2. U.K.
10.3.7.3. France
10.3.7.4. Spain
10.3.7.5. Italy
10.3.7.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.7.1. Brazil
10.4.7.2. Argentina
10.4.7.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.7.1. China
10.5.7.2. India
10.5.7.3. Japan
10.5.7.4. South Korea
10.5.7.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Neurocrine Biosciences, Inc.*
12.1.1. Company Overview
12.1.2. Product Portfolio
12.1.2.1. Product Description
12.1.2.2. Product Key Performance Indicators (KPIs)
12.1.2.3. Historic and Forecasted Product Sales
12.1.2.4. Product Sales Volume
12.1.3. Financial Overview
12.1.3.1. Company Revenue’s
12.1.3.2. Geographical Revenue Shares
12.1.3.3. Revenue Forecasts
12.1.4. Key Developments
12.1.4.1. Mergers & Acquisitions
12.1.4.2. Key Product Development Activities
12.1.4.3. Regulatory Approvals, etc.
12.1.5. SWOT Analysis
12.2. Pfizer Inc.
12.3. Johnson & Johnson Services, Inc.
12.4. AdvaCare Pharma
12.5. Teva Pharmaceuticals USA, Inc.
12.6. Sandoz
12.7. THE SEARLE COMPANY LTD.
12.8. Spruce Biosciences, Inc.
12.9. Crinetics Pharmaceuticals, Inc.
12.10. BridgeBio Inc.
12.11. H. Lundbeck A/S
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us